Related Experiment Video
Updated: May 17, 2026
10:38
Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
Published on: May 9, 2020
The kynurenine pathway in brain tumor pathogenesis
Seray Adams1, Nady Braidy, Alban Bessede
1Department of Pharmacology, School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia.
Cancer Research
|November 13, 2012
Summary
The kynurenine pathway (KP) is dysregulated in brain tumors, promoting immune evasion and neurotoxicity. Targeting KP enzymes like TDO-2 and IDO-1 offers a promising strategy for brain cancer therapy.
Area of Science:
- Neuro-oncology
- Immunology
- Metabolic pathways
Background:
- Malignant gliomas are chemoresistant with poor prognosis.
- The kynurenine pathway (KP) catabolizes L-tryptophan, producing neuroactive metabolites and NAD(+).
- KP dysregulation contributes to immune suppression and tumor progression in brain cancers.
Purpose of the Study:
- To review the role of kynurenine pathway dysregulation in brain tumor immune evasion.
- To highlight the significance of KP metabolites and enzymes in tumor progression and neurotoxicity.
- To identify potential therapeutic targets within the KP for brain cancer treatment.
Main Methods:
- Literature review of studies on the kynurenine pathway in brain tumors.
- Analysis of the roles of specific KP enzymes (IDO-1, TDO-2, ACMSD) and metabolites (QUIN, KYN, 3-HAA).
- Examination of the TDO-2-KYN-AhR signaling pathway in tumor immunity.
Main Results:
- KP dysregulation, including quinolinic acid (QUIN)-induced neurotoxicity and ACMSD downregulation, promotes brain tumor progression.
- KP metabolites like L-kynurenine (KYN) and 3-hydroxyanthranilic acid (3-HAA) mediate immunosuppression.
- Indoleamine 2,3-dioxygenase (IDO-1) and Tryptophan 2,3-dioxygenase (TDO-2) are key enzymes involved in tumor immune evasion.
- The TDO-2-KYN-AhR pathway represents a novel mechanism for brain tumor immune suppression and growth.
Conclusions:
- The kynurenine pathway is a critical regulator of the tumor microenvironment in brain cancers.
- Targeting KP enzymes (TDO-2, IDO-1, ACMSD) presents a viable therapeutic strategy.
- Inhibiting the KP may mitigate neurotoxicity and overcome immune suppression in brain tumors.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:19Cushing Syndrome II: Pathophysiology
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:28Biosynthesis of Nucleic Acids
Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...